A study of belumosudil in children with chronic graft versus host disease (schoolROCK)

Trial Identifier: DFI17893
Sponsor: Sanofi
Collaborator:
Meiji Seika Pharma Co., Ltd.
Start Date: December 2025
Primary Completion Date: February 2031
Study Completion Date: February 2031
Condition: Graft Versus Host Disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BELGIUM Gent, BELGIUM, 9000
BELGIUM Leuven, BELGIUM, 3000
CANADA, Ontario TORONTO, Ontario, CANADA, M5G 1X8
CHINA Beijing, CHINA, 100045
CHINA Shanghai, CHINA, 200040
CHINA Shenzhen, CHINA, 518026
CHINA Suzhou, CHINA, 215025
FRANCE Marseille, FRANCE, 13885
FRANCE Paris, FRANCE, 75019
GERMANY Berlin, GERMANY, 13353
ISRAEL Haifa, ISRAEL, 3109601
ISRAEL Jerusalem, ISRAEL, 9112001
ISRAEL Petah Tikva, ISRAEL, 4920235
ISRAEL Ramat Gan, ISRAEL, 5262100
ISRAEL Tel Aviv, ISRAEL, 6423906
ITALY, Milano Milan, Milano, ITALY, 20122
ITALY, Roma Rome, Roma, ITALY, 00165
NETHERLANDS Utrecht, NETHERLANDS, 3584 CS
SPAIN Barcelona, SPAIN, 08035
SPAIN, Barcelona [Barcelona] Esplugues De Llobregat, Barcelona [Barcelona], SPAIN, 08950
SPAIN, Madrid Madrid, SPAIN, 28009
TURKEY Ankara, TURKEY, 06800
TURKEY Izmir, TURKEY, 35100
UNITED KINGDOM, England Newcastle Upon Tyne, England, UNITED KINGDOM, NE2 4HH
UNITED KINGDOM, London, City of London, London, City of, UNITED KINGDOM, WC1N 3JH
UNITED STATES, California Los Angeles, California, UNITED STATES, 90027
UNITED STATES, District of Columbia Washington, District of Columbia, UNITED STATES, 20010
UNITED STATES, New York New York, UNITED STATES, 10065
UNITED STATES, Texas Houston, Texas, UNITED STATES, 77030